Ipca Laboratories Limited Overview
Pro stress-test →Ipca Laboratories is a fully integrated Indian pharmaceutical company founded in 1949, manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) across diverse therapeutic segments. The company operates globally, exporting to over 100 countries while maintaining 18 manufacturing units in India, positioning itself as one of India's top 20 pharmaceutical companies.
Strategic Profile
Pro stress-test →Ipca's competitive advantage lies in its backward-integrated operations focused on supply chain reliability and cost competitiveness, with nearly 79% of API exports serving international markets. The company is diversified across multiple therapeutic areas including cardiology, malaria, diabetes, and anti-malarial segments, with recent expansion through strategic acquisitions and a new ₹182 crore API manufacturing facility that commenced production in February 2026.
Competitive Landscape
Pro stress-test →Ipca operates in India's fragmented pharmaceutical market dominated by players like Cipla, Dr. Reddy's, Aurobindo, and Sun Pharma. The company differentiates through integrated operations (both APIs and formulations), strong API export capability, and therapeutic segment diversification. While competing in high-volume generic segments, Ipca's backward integration provides cost and supply chain advantages.
Industry Context
Ipca Laboratories Limited operates in Pharmaceuticals - Drug Manufacturers (Specialty & Generic).
Key facts
Founded: 1949 · Headquarters: Mumbai, India · Employees: 16,778 · Revenue: ₹2,556.50 crore (Q2 FY26) · Market cap: ₹36,589 crore